## With Cirrhosis

**TABLE 126: SVR GENOTYPE 2 WITH CIRRHOSIS TREATMENT-EXPERIENCED: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL**

| TREATMENT | REFERENCE | RR (95% CRI) | RD % (95% CRL) |
|---|---|---|---|
| SOF16 + RBV16 | SOF12 + RBV12 | 1.05 (0.71 to 1.41) | 3.80 (−22.57 to 25.33) |
| SOF12 + PR12 | | 1.29 (0.99 to 1.64) | 21.20 (−1.07 to 37.97) |
| SOF12 + PR12 | SOF16 + RBV16 | 1.23 (0.89 to 1.79) | 17.53 (−9.56 to 42.81) |
| | | | |
| Random effect model | Residual deviance | 6.875 vs. 8 data points | |
| | Deviance information criteria | 31.534 | |
| Fixed effect model | Residual deviance | 6.92 vs. 8 data points | |
| | Deviance information criteria | 31.468 | |

CrI = credible interval; PR = pegylated interferon plus ribavirin; RBV = ribavirin; RD = risk difference; RR = relative risk; SOF = sofosbuvir; SVR = sustained virologic response; vs. = versus.
Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.